ENCORAFENIB, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Binimetinib placebo, BINIMETINIB, Encorafenib Pacebo
C4221016
Phase 3 small_molecule active
Quick answer
ENCORAFENIB, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Binimetinib placebo, BINIMETINIB, Encorafenib Pacebo for Metastatic or unresectable locally advanced BRAF V600E/K mutation positive melanoma is a Phase 3 program (small_molecule) at Pfizer Ireland Pharmaceuticals Unlimited Company with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pfizer Ireland Pharmaceuticals Unlimited Company
- Indication
- Metastatic or unresectable locally advanced BRAF V600E/K mutation positive melanoma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active